Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that its oral weight loss therapy medicine successfully completed its Phase 3 ...

On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 ...

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant announced positive results from a Phase 3 trial of its oral weight loss pill, paving the way for ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight and type 2 diabetes, showed that the oral ...

Eli Lilly and Company has confirmed it’s selling its manufacturing site in Branchburg. The decision was made following a ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...

The main reason Eli Lilly's shares dipped significantly after the earnings announcement is that the company also released ...

Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli ...